Schedule 13G ownership disclosure

Kymera Therapeutics Inc

Common Stock · CUSIP: 501575104

Event date: 2025-03-31

Filing-level shares
5,231,392
Percent of class
8.05%
  • The Vanguard Group

    Shares: 5,231,392 · Class: 8.05%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000932471-25-000559
Form type
SCHEDULE 13G/A
Filer
Kymera Therapeutics, Inc.
CIK
CIK 1815442
Filed
Apr 30, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub